Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoBMY +2.87%71 Equity-to-Asset is 0.26 as of Jun. 2026, which is 21% below its 10-year median of 0.33. GuruFocus rates BMY with a GF Score™ of 71/100 and a GF Value™ of $56.49 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks worse than 85.47% on this metric.
Bristol-Myers Squibb Co (NYSE:BMY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bristol-Myers Squibb Co Equity-to-Asset Related Terms
Bristol-Myers Squibb Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMY vs PFE, GILD, AMGN: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Equity-to-Asset falls into.
Bristol-Myers Squibb Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bristol-Myers Squibb Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (BMY) has a Equity-to-Asset of 0.26 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bristol-Myers Squibb Co and its competitors. This is 21% below median its historical median of 0.33. Over the past decade, Bristol-Myers Squibb Co's Equity-to-Asset has ranged from 0.17 to 0.48. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #859 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 85.5%.
Is Bristol-Myers Squibb Co's Equity-to-Asset too high?
Bristol-Myers Squibb Co's current Equity-to-Asset of 0.26 is 21% below median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.48. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Bristol-Myers Squibb Co's value of 0.26 is 57.4% below this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #859 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Equity-to-Asset compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #859 out of 1005 companies for Equity-to-Asset. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Bristol-Myers Squibb Co's value of 0.26 is 57.4% below this benchmark. Historically, Bristol-Myers Squibb Co's own Equity-to-Asset has ranged from 0.17 to 0.48 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 0.61, Bristol-Myers Squibb Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Equity-to-Asset of 0.26 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Equity-to-Asset is 0.26, which is 21% below median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $56.49, compared to a current price of $67.35 — trading 19.2% above its estimated fair value. The current Equity-to-Asset is 0.26, which is 21% below median its 10-year median of 0.33 and 57.4% below the Drug Manufacturers industry median of 0.61. Bristol-Myers Squibb Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BMY), the current Equity-to-Asset is 0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $67.35 is trading 19.2% above its estimated GF Value™ of $56.49.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for BMY:
Equity-to-Asset: 0.26 (21% below median its 10-year median of 0.33)
GF Value™: $56.49 vs. price of $67.35 (19.2% above fair value)
Industry Position: 57.4% below the Drug Manufacturers median (#859 of 1005)
No single metric tells the full story. See the BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score
Get the complete analysis for BMY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMY has been successfully added to your 
